OS Therapies Inc
OS Therapies Inc (OSTX): 5 pipeline candidates · ~1 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
0.6 months
D/E -1.58 · 0% dilution
Lead: Phase 2
5 candidates
N/A
N/A
A transparent, data-derived signal for OS Therapies Incacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$76.6M
Cash
$918K
Quarterly Burn
$4.6M
Runway
0.6 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| adxs-503 | Preclinical |
| adxs-504 | Preclinical |
| ost-her2 | Phase 2 |
| ost-tadc | Preclinical |
| ost-tadc-a | Preclinical |
Frequently asked questions
How many drug candidates are in OS Therapies Inc's pipeline?
OS Therapies Inc (OSTX) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is OS Therapies Inc's lead drug candidate?
OS Therapies Inc's most advanced tracked candidate is adxs-503 (Preclinical) for Non-small cell lung cancer.
What is OS Therapies Inc's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, OS Therapies Inc has approximately 0.6 months of cash runway.
What is OS Therapies Inc's market capitalization?
OS Therapies Inc's market capitalization is approximately $76.6M.
Who is the CEO of OS Therapies Inc?
Mr. Paul A. Romness M.P.H. is the chief executive officer of OS Therapies Inc (OSTX).
Get the full picture on OS Therapies Inc
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.